Evidence map›Paper›PMID 20594861›Full record

ArticleBioorganic & medicinal chemistry2010

Target-specific control of lymphoid-specific protein tyrosine phosphatase (Lyp) activity.

Zandra E Walton, Anthony C Bishop

Open access · greenAbstract read
In one paragraph

Article in Bioorganic & medicinal chemistry, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Direct Chemical Activation of a Rationally Engineered Signaling Enzyme.Chembiochem : a European journal of chemical biology · 2015
    Article
  3. Article
  4. Arsenic binding to proteins.Chemical reviews · 2013
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Zandra E WaltonAmherst College, Department of Chemistry, Amherst, MA 01002, United States.
Anthony C Bishop
Amherst College · US

Funding

Target-specific inhibition and activation of protein tyrosine phosphatasesR15GM071388 · NIGMS · AMHERST COLLEGE · PI BISHOP, ANTHONY C · 2005 to 2021
$1.6M
NIGMS NIH HHS 2 R15 GM071388-02NIGMS NIH HHS R15 GM071388
6 · The paper itself

Abstract

Lymphoid-specific protein tyrosine phosphatase (Lyp), a member of the protein tyrosine phosphatase (PTP) superfamily of enzymes, is an important mediator of human-leukocyte signaling. Lyp has also emerged as a potential anti-autoimmune therapeutic target, owing to the association of a Lyp-activating mutation with an array of autoimmune disorders. Toward the goal of generating a selective inhibitor of Lyp activity that could be used for investigating Lyp's roles in cell signaling and autoimmune-disease progression, here we report that Lyp's PTP domain can be readily sensitized to target-specific inhibition by a cell-permeable small molecule. Insertion of a tetracysteine-motif-containing peptide at a conserved position in Lyp's catalytic domain generated a mutant enzyme (Lyp-CCPGCC) that retains activity comparable to that of wild-type Lyp in the absence of added ligand. Upon addition of a tetracysteine-targeting biarsenical compound (FlAsH), however, the activity of the Lyp-CCPGCC drops dramatically, as assayed with either small-molecule or phosphorylated-peptide PTP substrates. We show that FlAsH-induced Lyp-CCPGCC inhibition is potent, specific, rapid, and independent of the nature of the PTP substrate used in the inhibition assay. Moreover, we show that FlAsH can be used to specifically target overexpressed Lyp-CCPGCC in a complex proteomic mixture. Since the mammalian-cell permeability of FlAsH is well established, it is likely that FlAsH-mediated inhibition of Lyp-CCPGCC will be useful for specifically targeting Lyp activity in engineered leukocytes and autoimmune-disease models.

Indexed as

MutationProtein EngineeringAmino Acid SequenceCatalytic DomainEnzyme InhibitorsEscherichia coliGene ExpressionHumansModels, MolecularMolecular Sequence DataProtein Tyrosine Phosphatase, Non-Receptor Type 22Sequence AlignmentEnzyme InhibitorsProtein Tyrosine Phosphatase, Non-Receptor Type 22

Identifiers

PMID20594861
PMCPMC2915760
OpenAlexW2062856746

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.